It's obvious that the company has a good shot at returning to growth.

Biogen says it expects revenue to fall in 2026 as its multiple sclerosis therapies continue to struggle.

Biogen BIIB will report fourth-quarter and full-year 2025 results on Feb. 6, before market open. In the last reported quarter ...

Biogen (BIIB) stock gains as the company beats estimates for Q4 2025 despite projecting a revenue decline for 2026. Read more ...

At Yahoo Finance, you get free stock quotes, up-to-date news, portfolio management resources, international market data, social interaction and mortgage rates that help you manage your financial life.

Biogen (NASDAQ:BIIB) outlined its immunology and neurology development priorities during a virtual symposium hosted by Piper ...

On February 11, 2026, Biogen announced that Caroline Dorsa, Chair of the company’s Board of Directors, will not stand for re-election at the 2026 Annual Meeting of Stockholders. The company stated ...

Biogen is transitioning from a shrinking MS franchise to a portfolio anchored in rare disease and Alzheimer’s therapies, ...

This was the stock's second consecutive day of losses.

Biogen Inc. (NASDAQ: BIIB) has steadily declined since peaking at $468.55 in 2021, as shares are trading down 70.64% from those highs to 12-year lows at $137.33. The medical sector biotechnology ...

Is Biogen (NASDAQ: BIIB) about to be acquired? One news article published on Wednesday reported that this is a possibility. As a result, the company's shares shot up almost 10% higher on the day. It ...